---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-036065"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:15:19.949604+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics approves new equity plan and amended CEO/CFO employment deals

## Summary
- Board approved 2024 Omnibus Plan (subject to stockholder vote) with 1,600,000 shares available for future awards.
- Contingent option grants: CEO Huntsman 315,421 ISOs, CFO Amman 149,533 ISOs at $2.62/share, 3-year vesting.
- Amended employment agreements effective Jan 1, 2025 raise CEO base salary to $450,000 and CFO to $320,000.
- Severance: 12-month salary continuation on non-cause termination; 24 months after change-in-control; full equity vesting.
- New plan will replace 2019 Plan; unused shares retired if stockholders approve at 2024 Annual Meeting.

## SEC filing metadata
- accession: 0001493152-24-036065
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315224036065/0001493152-24-036065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315224036065/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-036065
- JSON: https://secwatch.observer/filing/0001493152-24-036065.json
- Plain text: https://secwatch.observer/filing/0001493152-24-036065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.